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Abstract
Background: Because some Toxoplasma gondii genotypes may be more virulent in pregnant women,
discriminating between them appears valuable. Currently, the main genotyping method is based on single copy
microsatellite markers, which limit direct genotyping from amniotic fluids (AFs) to samples with a high parasitic
load. We investigated whether the multicopy gene B1 could type the parasite with a higher sensitivity. To estimate
the amplifiable DNA present in AFs, we first compared three different PCR assays used for Toxoplasma infection
diagnosis: the P30-PCR, targeting the single copy gene P30; the B1-PCR, targeting the repeated B1 gene; and
RE-PCR, targeting the repeated element.
Results: Of the 1792 AFs analyzed between 2008 and 2011, 73 were RE-PCR positive. Of those, 49 (67.1%) were
P30-PCR and B1-PCR positive, and 14 (19.2%) additional AFs were B1-PCR positive only.
All 63 BI-positive AFs (France n = 49; overseas n = 14) could be genotyped based on an analysis of eight nucleotide
polymorphisms (SNPs) located within the B1 gene. Following high-resolution melting (HRM) analysis, minisequencing
was carried out for each of the eight SNPs. DNA from six reference strains was included in the study, and AFs were
assigned to one of the three major lineages (Types I, II, and III). In total, 26 genotypes were observed, and the
hierarchical clustering distinguished two clades in lineages II (IIa, n = 30 and IIb, n = 4) and III (IIIa n = 23 and
IIIb n = 6). There was an overrepresentation of overseas isolates in Clade IIb (4/4, 100%) and Clade IIIa (8/22; 36.4%)
(p <0.0001), whereas medical interruption and fetal death were overrepresented in Clade IIb (2/4, 50%) and Clade IIIa
(4/23, 17.4%) (p = 0.049).
Conclusions: Although the current genotyping system cannot pretend to replace multilocus typing, we clearly show
that targeting the multicopy B1 gene yields a genotyping capacity of AFs around 20% better than when single copy
targets are used. The present genotyping method also allows clear identification of genotypes of potential higher
virulence.
Keywords: Toxoplasma gondii, P30 gene, B1 gene, AF487550 repeated element, Genotyping, Minisequencing analysis
* Correspondence: jmcosta@lab-cerba.com
†Equal contributors
1Laboratoire CERBA, Paris, Cergy-Pontoise, France
Full list of author information is available at the end of the article
© 2013 Costa et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Costa et al. BMC Infectious Diseases 2013, 13:552
http://www.biomedcentral.com/1471-2334/13/552
Background
Infection by the protozoan parasite Toxoplasma gondii
can yield symptoms ranging from asymptomatic infec-
tions to miscarriages or meningoencephalitis in im-
munocompromised patients. In prenatal infections, fetal
damages are usually linked to the time of infection dur-
ing the pregnancy. The earlier on, the more likely mis-
carriages and severe debilitating infections become [1].
However, genotyping has revealed genetic diversity in
this worldwide parasite, and three main lineages (Types
I, II, and III) [2], now grouped into 15 haplogroups in
six major clades, have been described [3]. Setting aside
epidemiological and taxonomic studies, genotype deter-
mination is clinically relevant, as some genotypes harbor
a specific virulence [4-6]. The need for a simple geno-
typing system, effective in clinical specimens, is clear.
Microsatellite markers have emerged as a very con-
venient means for direct genotyping since first reported
[7]. Up to 15 markers in a multiplex PCR format are
now suggested for genotyping [8]. However, only 62%
(15/24) of the AFs sent to the French National Center
for toxoplasmosis could be genotyped (http://cnrtoxo
plasmose.chu-reims.fr/wp-content/uploads/2012/10/CNR-
TOXOPLASMOSE-RAPPORT-ACTIVITES-2011.pdf ).
The small amount of DNA extracted from clinical samples
for single locus typing of microsatellite markers probably
explains this dearth of typable isolates. Testing microsatel-
lite markers on samples with low T. gondii DNA content
can lead to the absence of detectable peaks or peaks of
low intensity not easily distinghishable from non specific
PCR products [8]. Consequently, if for any reason the
non-typable samples correspond to specific genotypes,
correlations drawn between symptoms and genotypes or
conclusions on epidemiologic trends could be biased.
Several options for improving the rate of typability
exist. One possibility is to cultivate the parasite before
DNA extraction. However, cultures introduce bias, as
not every isolate will grow with the same efficiency. The
risk of false positives, especially in the context of a rou-
tine laboratory dealing with pregnant women, precludes
a nested PCR format [9]. Hence, our choice was to use
a multicopy gene as a target. We recently investigated
the possibility of genotyping T. gondii using the poly-
morphism of the repeated B1 gene with high-resolution
melting (HRM) analysis and minisequencing (SNaPshot)
using reference strains of different types [10]. Our typ-
ing system using B1 was based on a single PCR amp-
lification whose yield is easy to manage with an internal
control [11] (as opposed to a multiplex PCR, where
failure of one of the primer sets can have multiple
causes).
We present here the results of analysis of the amni-
otic fluids (AFs) sent to our laboratory under suspi-
cion of congenital toxoplasmosis. We added a formal
comparison of the three targets used for Toxoplasma
infection diagnosis: the single copy gene P30 [12], the
repeated B1 gene [13], and the repeated element (RE)
[14]. Besides this previously unreported comparison,
our aim was to find clues indicating the presence of
amplifiable DNA in the sample.
Methods
Samples
Between 2008 and 2011, 1792 AFs were analyzed for the
presence of T. gondii DNA. Tests were required because
of proven or suspected maternal infection following sys-
tematic serological screening for anti-Toxoplasma anti-
bodies (n = 1309; 73%), as required by French regulations
[15], or for investigation of abnormalities revealed upon
ultrasound examination (n = 483; 27%). Samples were sent
from 465 different medical centers in France and overseas
(French Caribbean, French Guyana, La Réunion Island,
New Caledonia, and North Africa). After analysis, the
remaining material was stored at -80°C, Informed consent
for AF sampling, biochemical and microbiological testing,
and data analysis was obtained from all women. In com-
pliance with French regulations of prenatal diagnoses,
patients provided informed consent for sample collec-
tion and analysis. Local ethics committee approval was
not required, as the procedures were part of routine
care. The French National Commission on Computing
and Freedom was notified of the database (registration
number: 1406332).
Toxoplasma gondii DNA detection
Total DNA was extracted from one ml of each AF using
the Total Nucleic Acid Isolation kit (Roche Diagnostics,
Meylan, France) on a MagNA Pure Compact apparatus,
in accordance with the manufacturer's instructions.
DNA was eluted with 100 μl of elution buffer, of which
5 μl were used for each PCR assay. Each AF was tested with
three quantitative PCR (qPCR) assays targeting the P30
gene (P30-PCR; GenBank access number AY187278), the
B1 gene (B1-PCR; GenBank access number AF179871),
and the repeated element (RE-PCR; GenBank access
number AF487550) [16], as previously described [17].
PCR reactions were carried out in a LightCycler
LC480 Instrument (Roche Diagnostics, Meylan, France)
in a final volume of 20 μl, using the LC480 Probes
Master Kit (Roche Diagnostics, Meylan, France) with
0.5 μM of each primer and 0.25 μM of each probe.
Following an initial incubation step of 1 minute at
50°C and a denaturation step of 10 minutes at 95°C, ampli-
fication was performed for 50 cycles of denaturation
(95°C, 10 seconds, and ramping rate 4.4°C/second), an-
nealing (56°C, 10 seconds, and ramping rate 2.2°C/second),
and extension (72°C, 15 seconds, and ramping rate
4.4°C/second).
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Toxoplasma gondii genotyping
If detectable for the B1 gene, T. gondii DNA was geno-
typed based on an analysis of eight nucleotide polymor-
phisms (SNPs) located within the B1 gene, as described
elsewhere [10]. All SNPs were studied during a single in-
dependent PCR in a final volume of 20 μl with the High
Resolution Melting Master Kit (Roche Diagnostics,
Meylan, France), 3 mM MgCl2, and each primer (Sigma,
Paris, France) at a concentration of 0.5 μM. The reaction
mixture was initially incubated for 10-min steps at 95°C.
Amplification was performed for 50 cycles of denaturation
(95°C for 10 sec; ramp rate, and 4.4°C/s), annealing (60°C
for 10 sec; ramp rate, and 2.2°C/s), and extension (72°C
for 15 sec; ramp rate, and 4.4°C/s) in a LightCycler 480
Instrument (Roche Diagnostics, Meylan, France). HRM of
PCR products was then performed at 95°C for 1 min,
at 40°C for 1 min, and with increasing temperature from
65°C to 95°C at a rate of 1°C/s with 25 acquisitions per °C.
Following purification of the PCR products with ExoSAP-
IT (USB Europe, Staufen, Germany), SNaPshot analysis
was carried out using the SNaPshot Multiplex kit (Applied
Biosystems, Courtaboeuf, France) for each of the eight
examined SNPs, and the reactions were run on an
ABI3130XL genetic analyzer and analyzed using the
Genescan software. DNA from reference strains for each
of the three main lineages, Type I (RH strain), Type II
(B7 strain), and Type III (C5 strain), were kindly pro-
vided by Asis Khan (David Sibley laboratory), while strains
from Africa (Africa 1 [RMS-2003-DJO] and Africa 2
[CCH-2004-NIA]), and the Caribbean (CCH-2005-REN)
were purchased from the French National Center of
Reference for toxoplasmosis.
Toxoplasma gondii genotype analysis and
genotype-clinical data association
Genotypes were determined for the B1-PCR positive
AFs and six reference strains based on determinations
of the transition/transversion matrix [18] for each
locus tested with SNaPshot analysis. The predominant
allele (>50% of the samples) was considered the wild-
type allele, and was used as the reference sequence.
The polymorphic allele was then classified according to
the transition/transversion matrix. In the case of heterozy-
gosity (a double peak at the polymorphic locus), indicating
a variable proportion of polymorphic repeated sequence,
50% of the corresponding transition/transversion matrix
value was arbitrary attributed.
Based on the combination of the eight markers, we de-
termined the final genotype using an arbitrary implementa-
tion. Relatedness between the different genotypes was
evaluated based on hierarchical clustering (complete link-
age; Euclidian distance metric) using the open-source gen-
omic analysis software MeV v4.6.1 (The TM4 Development
Group), obtained from http://mev.tm4.org [19]. The different
clades were arbitrarily determined using a threshold of
1.225 (Euclidian).
Statistical analysis and calculations
The graphs, Chi-squared tests, and ANOVA tests were
performed using Prism v4.0 (GraphPAD Software, San
Diego, CA). Fold changes from Ct values were calculated
following this formula : Fold change (FC) = 2-ΔCt.
Results and discussion
According to the RE-PCR assay, which is used for rou-
tine testing in our diagnostic laboratory [16], T. gondii
DNA was detected in 82/1792 (4.6%) AFs. Of the 82
infected AFs, 73 had enough sample left to be stored
at -80°C, and therefore were available for simultaneous
comparison of the three DNA targets. The nine AFs with
no DNA left for further analysis were from different tri-
mesters (seroconversion in first trimester n = 2, second tri-
mester n = 5, and unknown n = 2) and of different origin
(France n = 8; overseas n = 1); therefore, it is improbable
that their exclusion impacted the subsequent analysis. The
73 RE-PCR positive AFs came from 65 different cities and
43 different medical centers.
As our main objective was to characterize the infecting
T. gondii strains directly from the clinical specimen
using a multicopy gene target, we performed a compara-
tive study of the three main targets used for detecting
T. gondii (P30, B1 and RE) to get an idea of the quantity
of T. gondii DNA in the clinical samples. Indeed, the
Figure 1 Dot plot representation of the delta Ct comparing the
three PCR assays (P30-PCR, B1-PCR, RE-PCR) for 63 B1-PCR
positive AFs. Horizontal bars represent the mean and range of the
delta Ct for all the samples. The repetition of the genes B1 and RE
compared to P30, and RE compared to B1, varied among the clinical
variation within the fold variation indicated under each dot plot. The
mean gain of detection of B1 PCR and RE PCR compared to the P30
PCR are indicated on the right. Note the fourteen AFs that were
negative using P30-PCR.
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samples in which no amplification is observed when tar-
geting the single copy gene P30 are expected not to be
genotypable with a single copy marker. Although these
different targets have already been compared two-by-two
[16,20,21], this is the first simultaneous comparison with a
consistent number of samples (n = 73). The three qPCR
assays were positive in 49/73 (67.1%) samples, the B1-PCR
and RE-PCR assays were positive in 14/73 (19.2%) add-
itional samples, and the RE-PCR assays were positive in
the remaining 10/73 (13.7%) samples. Figure 1 shows the
comparison of quantitative cycle (Cq) function of the
target gene for each positive sample (n = 73). The varia-
tions of the number of repetitions for the B1 gene and RE
were 15.9 and 35 times, respectively, greater than those of
the single copy P30 gene (p <0.0001). Considering vari-
ation among the 73 samples, the B1-PCR and RE-PCR
increased detection by mean factors of 10 (-3.33 Ct)
[range 0.6 to 26] and 278 (-8.12 Ct) [range 27 to 948],
respectively, over the P30-PCR (Figure 1). Contrarily to
Wahad et al. [21], we did not observe B1-PCR positive
Figure 2 Hierarchical clustering of the matrix generated for the eight tested SNPs using minisequencing analysis for 63 B1-PCR
positive AFs and six reference strains. Clusters corresponding to the well-known lineages I, II and III were delineated. Using the arbitrary
threshold of 1.225, two additional clades could be separated in lineages II (IIa and IIb) and III (IIIa and IIIb). The names of the reference strains,
the origins of the samples, the names of the clades, and the number of the samples are indicated on the right. Clustering was calculated based
on Euclidian distance metrics and complete linkage. *Reunion I.: Reunion Island, F.guiana: French Guiana, N.Caled.: New Caledonia, Guadel.I.:
Guadeloupe Island.
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and RE-PCR negative samples, and we confirm here that
RE is the best target for toxoplasmosis investigation in
pregnant women [16].
As the current microsatellite typing method is based
on single copy targets [8], the use of a multicopy gene
such as B1 was expected to improve the number of
typable samples. Using the B1 gene, we increased
the number of typable infecting T. gondii from 67%
(49/73)—expected given the ability to amplify a single
copy gene—to 86% (63/73). However, the B1 gene’s
sensitivity does not compete to that of RE. Of the 73 AFs
available for genotyping studies, minisequencing analysis
was not possible in 10/73 (13.7%) samples. These 10 non-
genotypable AFs exhibited a RE-PCR Cq ranging from
32.4 to 36.3, i.e., a low quantity of T. gondii DNA. As a
consequence, we expected 10-15% of non-typable samples
to return positive only when using the RE-PCR assay. The
10 non-genotypable AFs were not associated with a given
trimester (seroconversion in second trimester n = 3, third
trimester n = 6, and unknown n = 1; p value = 0.26). These
10 non-typable AFs were all from France. This possible
association of low amount of T. gondii DNA with French
AFs might be due to comparatively early diagnoses due
to the monthly mandatory screening of seroconversion
during pregnacy instaured in France for several decades
(see below).
Genotyping based on B1 polymorphism was available
for the 63 B1-PCR positive clinical samples and the six
reference strains used, for which the DNA was extracted
from pure culture. For each of the eight SNP markers,
alleles were classified as wild-type, polymorphic, or mix-
ture. Based on this classification in three different states,
25 genotypes were observed, with two genotypes observed
only in the reference strains DJO and RH (Figure 2). Thus,
although targeting a single locus, the B1 gene’s rate of ob-
served polymorphism was high, with 46% (25/69) of
unique genotypes, confirming the marked genetic diversity
of the parasite [3]. Other DNA polymorphisms were ob-
served in B1 and could be explored in order to increase
discriminatory power if needed [10]. Based on a transi-
tion/transversion matrix analysis, hierarchical clustering
distinguished the three major lineages (Types I, II, and III),
as a reference strain of each lineage clustered in each of
the three groups. Using an arbitrary threshold of 1.225,
two clades were observed in lineages II (IIa, n = 30 and IIb,
n = 4) and III (IIIa n = 23 and IIIb n = 6). The Clade IIa
contained the reference strain B7, and the Clade IIIa the
reference strains C5, NIA, and REN. No clinical sam-
ple clustered with the Type I reference strains (DJO
and RH). Therefore, our system clearly distinguished
the RH strain and atypical strains from Type II and
Type III strains.
The repartition of the French and overseas samples was
significantly different in Clades IIa, IIb, IIIa and IIIb
(Figure 2), with an overrepresentation of overseas isolates
(p < .0001) in Clade IIb (4/4, 100%) and Clade IIIa (9/22,
36,4%). Among the 56 samples for which data was available,
the repartition of medical interruption and fetal death
versus no abnormality significantly differed in the four
clades, with an overrepresentation (p = 0.049) of medical
interruption and fetal death in Clade IIb (2/4, 50%) and
Clade IIIa (4/23, 17.4%). As already reported, the European
infections were mainly due to Type II strains [7,8], whereas
strains from French Carribean, French Guyana, and
Reunion Island were confirmed to be more grave [4,6].
However, seriousness depends not only on the genotype,
but also on numerous other factors, such as the time of
infection [1,7]. In our study, we were able to confirm the
association between medical interruption and fetal death
and the first trimester of seroconversion (p = 0.0032). One
might suspect that T. gondii infections during overseas
pregnancies were diagnosed later, resulting in poorer out-
comes. However, there was no association between the
four clades and the date of seroconversion (p = 0.51).
Similarly, seriousness was not associated (p = 0.33) with a
geographical origin. Therefore, lower standards of care in
overseas pregnancies are unlikely to bias the greater
seriousness of some clades.
Conclusions
Our study highlights the value of using the polymorph-
ism of the repeated B1 gene for directly genotyping
T. gondii from clinical specimens without the use of any
isolation or culture. Our typing system clearly individu-
alized four clades, including the three main lineages of
the parasite. Using the homogenous Type II genotype
for background, we were able to individualize overseas
genotypes with a higher virulence. However, we fully
recognize that taxonomic studies with a single locus are
limited, and therefore we did not attempt to further de-
velop our markers in this context.
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